Cellectar Biosciences Inc
CLRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.02M
Close$
$4.90
88.5% upside
Current Fair Value
88.5% upsideUndervalued by 88.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.02 Million |
|---|---|
| Enterprise Value | $3.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.35 |
| Beta | 0.43 |
| Outstanding Shares | 4,240,129 |
Return
| Return on Equity | -441.82% |
|---|---|
| Return on Assets | -187.42% |
| Return on Invested Capital | -359.03% |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | 4.44 |
| Price to Sales | - |
| Price to Book Ratio | 2.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.14 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.48 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.89
Average shareholder expectationRevenue Estimate
$8.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$12.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.33%▼ 5.97% |
|---|---|
| Total Invested | $812,903▼ 22.03% |
| Investors Holding | 19▼ 1.00% |
ESG Score
No data
About Cellectar Biosciences Inc
CEO: James Caruso